GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Inventiva S.A.
Inventiva is a French biotech company developing drugs to treat NASH and other metabolic diseases. Its stock price is driven by news of clinical trials. The chart reflects investor expectations for the success of its key drug in this competitive field.
Share prices of companies in the market segment - Pharma liver
Inventiva S.A. is a French biopharmaceutical company developing treatments for liver diseases, including nonalcoholic steatohepatitis. We have classified the company in the Pharma: Liver category. The chart below shows investor sentiment in this promising but risky biotech segment.
Broad Market Index - GURU.Markets
Inventiva S.A. is a French biopharmaceutical company developing drugs for the treatment of liver diseases. Its shares (ADR) are part of the GURU.Markets index. The chart below shows how its performance compares to the overall US market.
Change in the price of a company, segment, and market as a whole per day
IVA - Daily change in the company's share price Inventiva S.A.
Shares of Inventiva, a French biopharmaceutical company, are highly volatile. Change_co measures the market reaction to clinical trial data for its liver disease drug. This metric is an important component of formulas on System.GURU.Markets that assess risks in European biotech.
Daily change in the price of a set of shares in a market segment - Pharma liver
Inventiva S.A. is a biotech company. This chart demonstrates the extreme volatility of the sector. Comparison with IVA's performance, which focuses on liver disease treatments, helps to assess it as a high-risk, clinically data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Inventiva is a French biopharmaceutical company developing drugs for the treatment of liver diseases and fibrosis. This is a highly competitive and risky field. The chart below shows the segment's volatility, helping to assess how typical Inventiva's dynamics are for this niche.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Inventiva S.A.
Inventiva is a biopharmaceutical company specializing in the treatment of liver diseases. Its shares move in sync with news about clinical trials. This high, event-driven volatility feeds into the overall market flow.
Annual dynamics of market capitalization of the market segment - Pharma liver
Inventiva S.A. is a French clinical-stage biotechnology company developing drugs for the treatment of metabolic steatohepatitis (MASH) and other diseases. Its stock performance is entirely dependent on clinical trial results. The chart reflects high risks and breakthrough potential.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Inventiva is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its share price (ADR) reflects investor expectations for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Inventiva S.A.
Dave & Buster's, a unique chain of restaurants combined with amusement arcades, features monthly fluctuations that reflect consumer spending on entertainment and dining out. The success of its strategy to update its games and menu is a key factor in attracting customers.
Monthly dynamics of market capitalization of the market segment - Pharma liver
Inventiva S.A. is a French biopharmaceutical company focused on the treatment of liver diseases such as non-alcoholic steatohepatitis (NASH). This is a highly competitive and complex area of research. The chart below shows how investor sentiment has changed across the entire NASH treatment segment, driven by clinical trial news.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Inventiva is a French clinical-stage biopharmaceutical company focused on liver diseases. Its shares are embedded in the European biotech landscape, and their performance is driven by research results and European regulatory decisions, adding another layer of independence from the US market.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Inventiva S.A.
Inventiva is a French biotech company developing treatments for liver diseases. Its weekly stock price is volatile, driven by news of clinical trials and competitors' actions in this promising field.
Weekly dynamics of market capitalization of the market segment - Pharma liver
Inventiva is a French biotech company. Comparing its weekly performance with the European biotech sector will reveal how the market views its developments. The chart shows how news about clinical trials of its liver disease drugs differentiates it from its competitors.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Shares of Inventiva, a biotech company, live in a world of their own. Their performance is driven by clinical trial data. A comparison chart with the S&P 500 clearly demonstrates how the stock can rise or fall, completely ignoring the broader market.
Market capitalization of the company, segment and market as a whole
IVA - Market capitalization of the company Inventiva S.A.
Inventiva's market capitalization chart is a focused bet on the treatment of nonalcoholic steatohepatitis (NASH), a "silent epidemic" of liver disease. The performance of this French biotech company reflects investor expectations for its lead drug. Every movement on the chart represents the market's reaction to clinical trial data in one of the hottest areas of pharmaceuticals.
IVA - Share of the company's market capitalization Inventiva S.A. within the market segment - Pharma liver
Inventiva is a French biopharmaceutical company specializing in the development of oral therapies for the treatment of fibrotic diseases, particularly NASH (a liver disease) and scleroderma. Its sector share reflects the potential of its leading pipeline. The chart below shows the market's confidence in its scientific platform.
Market capitalization of the market segment - Pharma liver
Inventiva is a French biopharmaceutical company developing drugs to treat fibrotic diseases, particularly nonalcoholic steatohepatitis (NASH). The chart below shows the overall market capitalization of the pharmaceutical sector. It illustrates the huge potential market for NASH treatment, where there are currently no approved drugs.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart shows the scientific search for a cure for nonalcoholic steatohepatitis (NASH), the "silent" epidemic of obesity. Inventiva is developing a drug to treat this liver disease. Its volatile pipeline reflects the results of clinical trials in the race for a multi-billion dollar market.
Book value capitalization of the company, segment and market as a whole
IVA - Book value capitalization of the company Inventiva S.A.
Inventiva's book value is derived from its intellectual property for drugs for the treatment of liver disease (NASH) and other fibrotic disorders, as well as its financial reserves. This represents scientific capital for clinical research. The chart shows how the biotech company manages its resources during the development and testing of its key molecules.
IVA - Share of the company's book capitalization Inventiva S.A. within the market segment - Pharma liver
Inventiva is a biotech company focused on developing drugs for liver diseases and fibrosis. Its main assets are research and development (R&D) and patents, not manufacturing plants. The chart shows a minimal share of physical assets, as it is an R&D-focused business.
Market segment balance sheet capitalization - Pharma liver
Developing liver disease treatments like Inventiva's is a knowledge-intensive but relatively "easy" business at the R&D stage. Its value lies in its patents. Compared to the capital-intensive pharmaceutical sector, the company's model doesn't require the ownership of large manufacturing plants.
Book value of all companies included in the broad market index - GURU.Markets
Inventiva's book value is not derived from its plants, but primarily from its research and development and capital focused on clinical trials of drugs for the treatment of non-alcoholic steatohepatitis (NASH) and other metabolic diseases. Its assets reflect its financial capacity for research. The chart illustrates the scale of this French biotech company.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Inventiva S.A.
For Inventiva, a French biotech, market capitalization is a bet on the success of its NASH drug. The ratio to book value (its cash value) indicates how much the market believes in the drug's potential to become a blockbuster.
Market to book capitalization ratio in a market segment - Pharma liver
Inventiva is a French biopharmaceutical company developing drugs to treat liver disease (NASH) and other conditions. Its valuation on this chart reflects investors' bet on the success of its clinical trials in a highly complex and competitive field.
Market to book capitalization ratio for the market as a whole
Inventiva is a French biopharmaceutical company developing drugs for the treatment of fibrotic diseases, particularly non-alcoholic steatohepatitis (NASH). Its valuation is a bet on success in treating this "disease of civilization." This metric reflects how the market assesses the potential of these drugs in a vast, yet complex, market.
Debts of the company, segment and market as a whole
IVA - Company debts Inventiva S.A.
Inventiva, a French clinical-stage biopharmaceutical company, is raising capital to fund the development of its drugs, particularly for the treatment of metabolic diseases. This schedule reflects its long-term investment needs to complete all stages of clinical trials and obtain regulatory approval.
Market segment debts - Pharma liver
Inventiva is a French clinical-stage biopharmaceutical company focused on developing drugs for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Drug development in this area is complex and expensive. This chart shows how the company raises capital, including debt, to fund its key clinical programs.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Inventiva S.A.
Inventiva is a French biopharmaceutical company focused on developing drugs for the treatment of liver diseases (NASH) and fibrosis. Clinical trials are a long and expensive process with uncertain outcomes. This chart shows how reliant the company is on debt financing to advance its molecules through the clinical trials to potential approval.
Market segment debt to market segment book capitalization - Pharma liver
Inventiva is a French biopharmaceutical company developing drugs to treat liver diseases such as NASH and other fibrotic conditions. This chart shows how the company finances its lengthy and expensive clinical trials, comparing its debt structure to the overall financial picture in the biotech sector.
Debt to book value of all companies in the market
Inventiva S.A. is a French biopharmaceutical company focused on the treatment of liver diseases and fibrosis. Clinical trials require significant funding, and companies often resort to debt financing. How dependent is Inventiva on its creditors? This graph of total debt in the economy helps assess its financial strategy and the risks to its success.
P/E of the company, segment and market as a whole
P/E - Inventiva S.A.
Inventiva is a French biopharmaceutical company developing drugs for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. This chart highlights the high investor expectations surrounding the discovery of an effective treatment for fatty liver disease. The valuation is highly sensitive to clinical trial results.
P/E of the market segment - Pharma liver
Inventiva is a clinical-stage biopharmaceutical company focused on developing oral therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases with unmet needs. This chart shows the average score for the sector, providing context for assessing Inventiva's scientific potential.
P/E of the market as a whole
Inventiva is a French biopharmaceutical company developing drugs to treat liver diseases such as NASH. The valuation of such companies often takes on a life of its own, depending on the success of clinical trials. Does comparing this chart reveal the extent to which Inventiva investors are ignoring broader market trends, betting solely on its science?
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Inventiva S.A.
Inventiva is a French biopharmaceutical company developing drugs to treat fibrotic diseases, particularly nonalcoholic steatohepatitis (NASH). This chart shows market expectations for the success of its clinical trials. Future profits depend on breakthroughs in the treatment of diseases for which there is currently no effective therapy.
%20P%2FE%20Inventiva%20S.A.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Inventiva-S.A.&v=1772587009742 "Chart of the company's future (projected) P/E Inventiva S.A.")
Future (projected) P/E of the market segment - Pharma liver
Inventiva is a French biopharmaceutical company in the clinical stage developing drugs for the treatment of fibrotic diseases, particularly nonalcoholic steatohepatitis (NASH). This chart reflects industry expectations, allowing investors to compare their hopes for the success of Inventiva's key drug with overall industry forecasts.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20liver&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-liver&v=1772587009773 "Future (projected) P/E graph of the market segment - Pharma liver")
Future (projected) P/E of the market as a whole
Inventiva S.A. is a French biopharmaceutical company working on treatments for liver diseases and fibrosis. Like many European biotechs listed in the US, its valuation depends on global investor interest in the sector. This chart shows the overall risk appetite that drives capital flows into knowledge-intensive industries.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772587009804 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Inventiva S.A.
Inventiva S.A. is a French biopharmaceutical company developing drugs for the treatment of non-alcoholic fatty liver disease (NAFLD) and other fibrotic disorders. Being in clinical development, its financial results reflect research expenses. The chart shows the cost of developing innovative drugs for unsolved medical problems.
Profit of companies in the market segment - Pharma liver
Inventiva is a French biopharmaceutical company developing drugs for the treatment of fibrotic diseases, particularly nonalcoholic steatohepatitis (NASH). This chart, which reflects the profitability of the pharmaceutical sector, illustrates the investment landscape. Inventiva's success depends on clinical trial results, and positive momentum in the sector helps attract capital for these purposes.
Overall market profit
Inventiva S.A. is a French biopharmaceutical company developing treatments for liver diseases, particularly nonalcoholic steatohepatitis (NASH). This represents a huge potential market. The success of such developments depends on the influx of capital into biotech. This chart shows the overall health of the economy, which influences investor willingness to fund long-term scientific research.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Inventiva S.A.
Inventiva is a French biopharmaceutical company developing oral therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases with unmet needs. This graph represents analyst expectations for the success of clinical trials and the potential of their lead candidate in a multi-billion-dollar market.
%20profit%20of%20the%20company%20Inventiva%20S.A.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Inventiva-S.A.&v=1772587010150 "Graph of future (projected) profit of the company Inventiva S.A.")
Future (predicted) profit of companies in the market segment - Pharma liver
Inventiva S.A. is a French clinical-stage biopharmaceutical company developing drugs for the treatment of fibrotic diseases, particularly non-alcoholic steatohepatitis (NASH). Its prospects depend on the success of clinical trials. This chart for the pharmaceutical sector shows the overall market expectations for innovative therapies in large but complex areas.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20liver&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-liver&v=1772587010167 "Graph of future (predicted) profits of companies in a market segment - Pharma liver")
Future (predicted) profit of the market as a whole
Inventiva S.A., a biopharmaceutical company developing drugs for the treatment of liver diseases, is valued based on scientific advances. However, overall economic expectations, illustrated by this chart, shape investors' risk appetite, which is critical for attracting funding for new research.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772587010212 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Inventiva S.A.
Inventiva S.A. is a French biopharmaceutical company developing drugs for the treatment of fibrotic diseases, particularly nonalcoholic steatohepatitis (NASH). This chart is crucial because it provides an estimate of future sales. Investors are betting on the success of its clinical programs in an area with a huge unmet medical need.
P/S market segment - Pharma liver
Inventiva S.A. is a biopharmaceutical company developing oral therapies for the treatment of liver diseases, including nonalcoholic steatohepatitis (NASH). Its valuation is based on future sales potential in a large and underserved market. This chart shows the industry average valuation, providing context for investor expectations for Inventiva's pipeline.
P/S of the market as a whole
Inventiva is a French clinical-stage biopharmaceutical company focused on developing oral therapies for the treatment of liver diseases (NASH) and mucopolysaccharidoses. This chart, which reflects revenue estimates for real businesses, highlights the investors' strong faith in Inventiva's scientific platform and the potential for its drugs to become blockbusters.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Inventiva S.A.
Inventiva is a French clinical-stage biopharmaceutical company focused on developing drugs for the treatment of fibrotic diseases, particularly non-alcoholic steatohepatitis (NASH). This schedule reflects investor expectations for successful completion of trials and entry into the multi-billion-dollar but highly competitive liver disease treatment market.
%20P%2FS%20Inventiva%20S.A.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Inventiva-S.A.&v=1772587010322 "The graph of the company's future (projected) P/S Inventiva S.A.")
Future (projected) P/S of the market segment - Pharma liver
Inventiva S.A. is a French clinical-stage biopharmaceutical company focused on developing oral therapies for the treatment of fibrotic diseases, particularly nonalcoholic steatohepatitis (NASH). This chart reflects average future revenue expectations in the pharmaceutical sector, providing an insight into how the market perceives Inventiva's potential.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20liver&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-liver&v=1772587010345 "Future (projected) P/S market segment graph - Pharma liver")
Future (projected) P/S of the market as a whole
Inventiva S.A. is a French biopharmaceutical company developing treatments for liver diseases, particularly nonalcoholic steatohepatitis (NASH). This graph reflects market expectations for future revenue. Inventiva's success depends on the results of clinical trials, which could offer the first effective treatment for millions of people with this "silent" disease.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772587010430 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Inventiva S.A.
This chart illustrates the revenue of Inventiva S.A., a clinical-stage biopharmaceutical company focused on developing oral therapies for liver diseases such as NAFLD. Its revenue at this stage may be modest and is tied to partnerships, reflecting research progress rather than ongoing commercial sales.
Sales of companies in the market segment - Pharma liver
Inventiva S.A. is a French biopharmaceutical company developing oral medications for the treatment of fibrotic diseases, particularly nonalcoholic steatohepatitis (NASH). This chart shows the potential market size for liver disease treatments. Inventiva's success could lead to the first approved treatment for NASH, creating a huge new segment in the industry.
Overall market sales
Inventiva S.A. is a French biopharmaceutical company developing drugs for the treatment of liver diseases and fibrosis. Its value is determined by progress in clinical trials. The overall economic situation, reflected in this chart, influences the investment climate in the biotech sector and the availability of financing.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Inventiva S.A.
Inventiva is a French biopharmaceutical company developing drugs for the treatment of liver diseases, particularly non-alcoholic steatohepatitis (NASH). The chart reflects analysts' expectations for the success of clinical trials and entry into the multi-billion dollar, but complex, NASH therapy market.
%20sales%20of%20the%20company%20Inventiva%20S.A.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Inventiva-S.A.&v=1772587010622 "Schedule of future (projected) sales of the company Inventiva S.A.")
Future (projected) sales of companies in the market segment - Pharma liver
Inventiva is a French biopharmaceutical company developing oral medications for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases with unmet needs. This chart shows the forecast for the entire pharmaceutical market, where NASH is considered one of the largest and most promising therapeutic areas of the future.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20liver&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-liver&v=1772587010685 "Schedule of future (projected) sales of companies in the market segment - Pharma liver")
Future (projected) sales of the market as a whole
Inventiva S.A. is a French biopharmaceutical company developing treatments for liver diseases and fibrosis. Its future depends on successful clinical trials and partnerships. The overall economic situation, reflected in this chart, influences the availability of capital for biotech, but scientific breakthroughs and regulatory decisions remain key factors for Inventiva.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772587010847 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Inventiva S.A.
Inventiva is a French biopharmaceutical company developing drugs for the treatment of liver disease (NASH) and other fibrotic disorders. Being in the clinical stage, it incurs significant R&D expenses. This chart shows its net losses—investments in research that could lead to the development of a sought-after drug on a huge market.
Market segment marginality - Pharma liver
Inventiva is a French clinical-stage biopharmaceutical company focused on developing oral therapies for the treatment of fibrotic diseases, particularly nonalcoholic steatohepatitis (NASH). Profitability is a long-term goal. This chart reflects clinical trial costs, which investors evaluate against the backdrop of a huge potential market.
Market marginality as a whole
Inventiva is a French biopharmaceutical company developing oral medications for the treatment of fibrosis, particularly nonalcoholic steatohepatitis (NASH), and other diseases. This overall profitability curve is not directly relevant to them. Their market capitalization depends on the success of clinical trials and the potential of their drugs to become standard treatments in their niche.
Employees in the company, segment and market as a whole
Number of employees in the company Inventiva S.A.
Inventiva is a French clinical-stage biotech company. Its team consists primarily of scientists and clinical development specialists. The growth in this chart is a clear signal that its lead drug candidates are successfully advancing into later, larger-scale phases of research.
Share of the company's employees Inventiva S.A. within the market segment - Pharma liver
Inventiva is a French biopharmaceutical company developing drugs for the treatment of liver diseases, including NASH, and other fibrotic diseases. This chart shows its share of the total number of researchers in this narrow therapeutic area. This increase indicates progress in clinical trials and the expansion of the scientific team working on new drugs.
Number of employees in the market segment - Pharma liver
Inventiva S.A. is a French biopharmaceutical company specializing in the development of oral drugs for diseases with high unmet medical need. This chart reflects the dynamics of employment in the narrow niche of drug development for liver diseases and fibrosis. The growing number of scientists here signals progress in clinical trials.
Number of employees in the market as a whole
Inventiva is a French biopharmaceutical company specializing in the development of drugs for the treatment of fibrotic diseases, particularly nonalcoholic steatohepatitis (NASH). This is one of the most pressing areas in medicine. This figure demonstrates how advances in the treatment of common diseases are creating new markets and stimulating employment in science and medicine.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Inventiva S.A. (IVA)
Inventiva S.A. is a French biotech company specializing in liver diseases (NASH). This chart reflects the net valuation of its intellectual capital. The company's value is based on expectations for its lead drug candidate. The chart shows how highly the market values a potential blockbuster developed by a relatively small team of scientists, per employee.
%20of%20the%20company%20Inventiva%20S.A.%20(IVA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Inventiva-S.A.-IVA&v=1772587011082 "Chart of market capitalization per employee (in thousands of dollars) of the company Inventiva S.A. (IVA)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma liver
Inventiva is a biopharmaceutical company developing drugs for liver diseases and fibrosis. Its value is based on its research potential. This chart demonstrates the high valuation of its intellectual capital and future prospects based on its small staff of highly qualified scientists, which is typical for R&D companies.
%20by%20market%20segment%20-%20Pharma%20liver&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-liver&v=1772587011088 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma liver")
Market capitalization per employee (in thousands of dollars) for the overall market
Inventiva is a French biopharmaceutical company developing drugs for the treatment of fibrotic diseases, particularly nonalcoholic steatohepatitis (NASH). The chart reflects the estimated scientific potential in a field with a huge market. The company's entire value is based on the hope of successful clinical trials.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772587011120 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Inventiva S.A. (IVA)
Inventiva is a French clinical-stage biotech company specializing in drugs for the treatment of fibrotic diseases, particularly nonalcoholic steatohepatitis (NASH). This research-intensive R&D program is a key focus for the company. This chart shows the research intensity: the amount of capital spent on each scientist attempting to solve one of the most complex problems in modern medicine.
%20Chart%20Inventiva%20S.A.%20(IVA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Inventiva-S.A.-IVA&v=1772587011155 "Company Profit Per Employee (in thousands of dollars) Chart Inventiva S.A. (IVA)")
Profit per employee (in thousands of dollars) in the market segment - Pharma liver
Inventiva (IVA) is a French clinical-stage biopharmaceutical company developing drugs for the treatment of liver diseases (NASH) and other conditions. This metric (loss per employee) reflects the high cost of R&D and clinical trials in this complex therapeutic area.
%20in%20the%20market%20segment%20-%20Pharma%20liver&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-liver&v=1772587011180 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma liver")
Profit per employee (in thousands of dollars) for the market as a whole
Inventiva S.A. is a French clinical-stage biotech company specializing in the treatment of NASH (liver disease) and other fibrotic diseases. The company is not profitable. This chart shows its capital burn rate: the operating loss per research team leading the development of a new drug through clinical trials.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772587011206 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Inventiva S.A. (IVA)
Inventiva is a biopharmaceutical company focused on developing drugs to treat fibrotic diseases, particularly liver disease. This chart reflects the progress of its research commercialization. The increase in revenue per employee at this stage is likely due to milestone payments from partners or licensing deals.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Inventiva-S.A.-IVA&v=1772587011258 "Sales chart per company employee Inventiva S.A. (IVA)")
Sales per employee in the market segment - Pharma liver
Inventiva is a French biopharmaceutical company focused on treatments for liver diseases (NASH) and fibrosis. For a clinical-stage company, this chart shows how efficiently their research team generates revenue (e.g., from partnerships) per employee, compared to other companies in the segment.
Sales per employee for the market as a whole
Inventiva (IVA) is a French clinical-stage biopharmaceutical company specializing in drugs for the treatment of fibrosis (including NAFLD) and oncology. The company does not yet have stable commercial revenue. This chart illustrates a typical biotech picture: its scientific and research staff is focused on R&D, which is an investment in future cash flows.
Short shares by company, segment and market as a whole
Shares shorted by company Inventiva S.A. (IVA)
Inventiva S.A. is a French biotech company developing drugs for the treatment of liver disease (NASH) and fibrosis. NASH is another complex area with numerous failures. This chart shows bearish investor sentiment, skeptical of the company's chances of success in late-stage clinical trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Inventiva-S.A.-IVA&v=1772587011347 "Short Shares Chart for the Company Inventiva S.A. (IVA)")
Shares shorted by market segment - Pharma liver
Inventiva is a French biotech company developing drugs to treat non-alcoholic steatohepatitis (NASH, or "fatty liver disease"). This chart shows bearish bets. "Shorts" here represent a bet on failure in the biotech "graveyard." Investors are betting that their NASH drug will fail.
Shares shorted by the overall market
Inventiva is a French biopharmaceutical company working on drugs for the treatment of liver diseases (NASH). European biotech stocks traded in the US (ADR) carry a double risk. When this chart shows rising panic, investors dump both speculative biotechs and foreign assets.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Inventiva S.A. (IVA)
Inventiva is a French clinical-stage biotech focused on MASH. The stock is extremely sensitive to trial news. This chart can soar above 70 on positive R&D data. A zone below 30 often reflects failures or general risk aversion in biotech.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Inventiva-S.A.-IVA&v=1772587011475 "RSI 14 indicator chart for the company's stock Inventiva S.A. (IVA)")
RSI 14 Market Segment - Pharma liver
Inventiva (IVA) is a French biotech company, a leader in the hot race to develop a cure for MASH (non-alcoholic steatohepatitis). The RSI_14_Seg for Pharma liver (biotech) reflects the overall sentiment. It helps us understand whether IVA's volatility is a reaction to their trials or just general hype.
RSI 14 for the overall market
Inventiva (IVA) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an easy way to raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast IVA (Inventiva S.A.)
Inventiva S.A. is a French biotechnology company developing oral therapies for the treatment of non-alcoholic steatohepatitis (NASH, "fatty liver") and other fibrotic diseases. This chart reflects analyst consensus. Their target prices are based on clinical trial data in NASH, one of the largest untapped markets in medicine.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-IVA-Inventiva-S.A.&v=1772587011601 "A chart showing analyst consensus forecasts for the expected stock price. IVA (Inventiva S.A.)")
The difference between the consensus estimate and the actual stock price IVA (Inventiva S.A.)
Inventiva (IVA) is a French biotech company whose lead drug (Lanifibranor) is in late-stage trials for the treatment of fatty liver disease (NASH). This chart is a barometer of their R&D. It measures the gap between the price and the consensus target, reflecting the high potential analysts see in their candidate for this billion-dollar market.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-IVA-Inventiva-S.A.&v=1772587011636 "A chart showing the difference between the consensus forecast and the actual stock price. IVA (Inventiva S.A.)")
Analyst consensus forecast for stock prices by market segment - Pharma liver
Inventiva (IVA) is a French biopharmaceutical company whose lead candidate, Lanifibranor, targets NASH (non-alcoholic steatohepatitis, also known as fatty liver disease). This chart shows overall expectations for the liver pharma sector, reflecting whether experts believe a breakthrough can be achieved in this "graveyard" of pharmaceutical developments.
Analysts' consensus forecast for the overall market share price
Inventiva (IVA) is a French clinical-stage biopharmaceutical company focused on the treatment of non-alcoholic steatohepatitis (NASH, fatty liver disease), a widespread but complex disease. This chart shows the overall risk appetite, reflecting the market's willingness to fund breakthrough, yet highly risky, scientific research.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Inventiva S.A.
Inventiva is a French biotech company racing to find a cure for NASH (non-alcoholic steatohepatitis, or fatty liver disease), one of the largest untapped markets in medicine. This chart represents pure R&D betting. It likely reflects the market's confidence in their clinical data (for Lanifibranor) and their chances of success in this highly competitive race.
AKIMA Market Segment Index - Pharma liver
Inventiva (IVA) is a French clinical-stage biotech focused on NASH/MASH (liver disease); the company is developing its candidate (Lanifibranor) for the treatment of this widespread disease. This summary metric evaluates R&D. The graph shows the segment average. This is a benchmark: how does this highly competitive (NASH) R&D rate (IVA) differentiate it from the average pharma company?
The AKIM Index for the overall market
Inventiva is a French biotech company developing oral drugs for the treatment of MASH (liver disease) and other conditions. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this speculative scientific story, racing for a blockbuster, compares to overall economic trends.
